Clinical Research Directory
Browse clinical research sites, groups, and studies.
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Sponsor: RayzeBio, Inc.
Summary
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Official title: A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-06-15
Completion Date
2027-11
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
RYZ211/212
Imaging Agent
Locations (6)
Research Facility
St Leonards, New South Wales, Australia
Research Facility
Nedlands, Australia
Research Facility
Perth, Australia
Research Facility
Christchurch, New Zealand
Research Facility
Johannesburg, South Africa
Research Facility
Pretoria, South Africa